Trial Profile
A Phase I/II, Open-label, 2 Arm Study to Investigate the Safety, Clinical Activity, Pharmacokinetics and Pharmacodynamics of GSK2879552 Administered Alone or in Combination With Azacitidine, in Adult Subjects With IPSS-R High and Very High Risk Myelodysplastic Syndromes (MDS) Previously Treated With Hypomethylating Agents (HMA)
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 26 Aug 2023
Price :
$35
*
At a glance
- Drugs GSK 2879552 (Primary) ; Azacitidine
- Indications Myelodysplastic syndromes
- Focus Adverse reactions; Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 23 Apr 2019 Status changed from recruiting to discontinued.
- 06 Jan 2018 This trial has been Discontinued in Spain (End date: 2017-12-14).
- 29 Nov 2017 This trial has been suspended in Spain.